GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer

Purpose G protein-coupled receptors (GPCRs) represent the largest family of druggable targets in human genome. Although several GPCRs can cross-talk with the human epidermal growth factor receptors (HERs), the expression and function of most GPCRs remain unknown in HER2+ breast cancer (BC). In this...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2018-07, Vol.170 (2), p.279-292
Hauptverfasser:	Bhat, Raksha R., Yadav, Puja, Sahay, Debashish, Bhargava, Dharmendra K., Creighton, Chad J., Yazdanfard, Sahar, Al-rawi, Ahmed, Yadav, Vikas, Qin, Lanfang, Nanda, Sarmistha, Sethunath, Vidyalakshmi, Fu, Xiaoyong, De Angelis, Carmine, Narkar, Vihang A., Osborne, C. Kent, Schiff, Rachel, Trivedi, Meghana V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Animals Antineoplastic Agents - pharmacology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer research Cell culture Cell growth Cell Line, Tumor Cell Proliferation - drug effects Disease Models, Animal Drug resistance Drug Resistance, Neoplasm Epidermal growth factor Epidermal growth factor receptors Epidermal growth factors ErbB-2 protein Female G protein-coupled receptors Gene expression Gene Knockdown Techniques Genes Genomes Genomics Growth factor receptors Humans Medicine Medicine & Public Health Mice Molecular Targeted Therapy Monoclonal antibodies Oncogene Proteins - genetics Oncogene Proteins - metabolism Oncology Parenting Preclinical Study Receptor mechanisms Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Receptors, G-Protein-Coupled - genetics Receptors, G-Protein-Coupled - metabolism Reproducibility of Results RNA, Small Interfering - genetics siRNA Targeted cancer therapy Trastuzumab Tumorigenicity Tumors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!